Marapharm Ventures Inc. (“Marapharm” or the “Company”) (www.marapharm.com) Further to its news release dated June 16, 2016, the Company is pleased to announce it has concluded the acquisition of a 75% interest in two additional medical marijuana licenses in Las Vegas, Nevada. The Company currently controls a provisional grow license in Las Vegas, where it is planning to build a medical marijuana facility of up to approximately 300,000 square feet. The plan is to merge all three licenses onto the 7-acre parcel of land and operate as a campus.
The City of North Las Vegas has approved the special use permits for all three licenses to be constructed on the land owned by Marapharm Las Vegas LLC. “Once the campus is complete, we will be one of the largest producers of Medical Marijuana in Nevada”.
For further information, please refer to the Company’s annual information form dated July 12, 2016 and filed under the Company’s profile on SEDAR on July 12, 2016.
ABOUT MARAPHARM VENTURES INC.
Additional information on the operations or financial results of Marapharm are included in reports on file with applicable securities regulatory authorities and may be accessed through the CSE website (www.thecse.com), the OTC website (www.otcmarkets.com), and the SEDAR website (www.sedar.com) under the profile for Marapharm Ventures Inc.
FOR FURTHER INFORMATION:
www.marapharm.com or 778-583-4476 email firstname.lastname@example.org
Neither the CSE, the FSE nor the OTCQB® has approved nor disapproved the contents of this press release. Neither the CSE, the FSE nor the OTCQB® accepts responsibility for the adequacy or accuracy of this release.
Certain statements contained in this news release constitute forward looking statements. The use of any of the words “anticipate”, “continue”, “estimate”, “expect”, ‘may”, “will”, “project”, “should”, ‘believe”, and similar expressions are intended to identify forward-looking statements. These statements involve known and unknown risks, uncertainties and other factors that may cause actual results or events to differ materially from those anticipated in such forward-looking statements are based on reasonable assumption but no assurance can be given that these expectations will prove to be correct and the forward-looking statements included in this news release should not be unduly relied upon.